Table 2

T2D patient characteristics by basal long-acting insulin analogue DET and GLAR
Detemir Glargine P-value
N (%) N (%) (χ2-test)
Total 251 47% 285 53%
Patient Characteristics
Female 101 40% 130 46% 0.2099
Male 150 60% 155 54%
Mean age 61 60 0.7123
<50 years 49 20% 63 22% 0.4629
≥50 years and <60 years 96 38% 103 36% 0.6145
≥65 years 106 42% 119 42% 0.9112
Mean weight (kilos) 86 87 0.2044
Mea height (cm) 172 172 0.4055
Mean BMI (kilos/m2) 29.1 29.8 0.3587
HbA1c value (%) 8.0 (63.9 mmol/mol) 8.2 (66.1 mmol/mol) 0.5602
Mean number of years on antdiabetic medication 11 10 0.068
Mean number of years on Determir/Glargine 2.1 2.2 0.2672
Geography
North Denmark Region 22 9% 26 9% 0.8849
Central Denmark Region 63 25% 32 11% 0.0000
Southern Denmark Region 66 26% 85 30% 0.3647
Region Sealand 43 17% 44 15% 0.5959
Capital region of Denmark 57 23% 98 34% 0.0029
Prescriber
GP 179 71% 159 56% 0.0002
Specialist 72 29% 126 44%
Concomitant insulin use
At least one product 110 44% 114 40% 0.3703
NovoRapid 79 31% 82 29% 0.4959
Actrapid 16 6% 4 1% 0.0024
Insuman Rapid 0 0% 4 1% 0.0596
Aprida 0 0% 3 1% 0.1031
Other insulin 18 7% 22 8% 0.8096
Non-insulin antdiabetic medication
At least one product 159 63% 188 66% 0.5267
Biguanides 146 58% 173 61% 0.5509
Sulfonomides 15 6% 16 6% 0.8578
Glitazoner (TZD) and combinations 0 0% 0 0%
DPP-IV inhibitors and combinations 8 3% 4 1% 0.1637
Victoza 26 10% 41 14% 0.1595
Byetta 0 0% 1 0% 0.3476

Jakobsen et al.

Jakobsen et al. BMC Endocrine Disorders 2012 12:21   doi:10.1186/1472-6823-12-21

Open Data